Xinru Zheng
YOU?
Author Swipe
View article: Machine learning-based differentiation of lung squamous cell carcinoma and adenocarcinoma using clinical-semantic and radiomic features
Machine learning-based differentiation of lung squamous cell carcinoma and adenocarcinoma using clinical-semantic and radiomic features Open
Purpose To evaluate and compare the predictive performance of machine learning methods using clinical-semantic, radiomic, and combined features in distinguishing squamous cell carcinoma (SCC) from adenocarcinoma (ADC) in non-small cell lun…
View article: Unveiling macrophage-centric immunomodulatory mechanisms of radix salviae miltiorrhizae in abdominal aortic aneurysm through integrated single-cell transcriptomic, network pharmacological, and molecular docking analyses
Unveiling macrophage-centric immunomodulatory mechanisms of radix salviae miltiorrhizae in abdominal aortic aneurysm through integrated single-cell transcriptomic, network pharmacological, and molecular docking analyses Open
Background: Abdominal aortic aneurysm (AAA) represents a fatal vascular disease with prevalence rates of 4–8 % among individuals over 65 years, and rupture mortality rates reaching 60–80 %. With accelerating population aging, AAA incidence…
View article: Correction for: D-galactose induces senescence of glioblastoma cells through YAP-CDK6 pathway
Correction for: D-galactose induces senescence of glioblastoma cells through YAP-CDK6 pathway Open
View article: Chiral Metasurfaces with Decoupled Intensity‐Phase Control for Multifunctional Optical Security and Holographic Displays
Chiral Metasurfaces with Decoupled Intensity‐Phase Control for Multifunctional Optical Security and Holographic Displays Open
Simultaneous and independent control of light's intensity and phase remains a critical challenge for multifunctional metasurfaces, as conventional designs suffer from inherent parameter correlations and orientation‐dependent limitations. H…
View article: Supplementary Figure 3 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplementary Figure 3 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer Open
Supplemental figure 3 and legend
View article: Supplementary Figure 5 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplementary Figure 5 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer Open
Supplemental figure 5 and legend
View article: Supplementary Methods from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplementary Methods from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer Open
Supplemental methods
View article: Supplementary Figure 4 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplementary Figure 4 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer Open
Supplemental figure 4 and legend
View article: Supplementary Figure 1 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplementary Figure 1 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer Open
Supplemental figure 1 and legend
View article: Supplementary Figure 2 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplementary Figure 2 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer Open
Supplemental figure 2 and legend
View article: Data from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Data from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer Open
Colorectal cancer is the second leading cause of cancer mortality in the United States. Although immune checkpoint blockade therapies including anti-PD-1/PD-L1 have been successful in treating a subset of patients with colorectal cancer, t…
View article: PACS2/CPT1A/DHODH signaling promotes cardiomyocyte ferroptosis in diabetic cardiomyopathy
PACS2/CPT1A/DHODH signaling promotes cardiomyocyte ferroptosis in diabetic cardiomyopathy Open
View article: Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer Open
Colorectal cancer is the second leading cause of cancer mortality in the United States. Although immune checkpoint blockade therapies including anti-PD-1/PD-L1 have been successful in treating a subset of patients with colorectal cancer, t…
View article: Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen
Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen Open
NLRP3, a crucial member of the NLRP family, plays a pivotal role in immune regulation and inflammatory modulation. Here, we report a potent and specific NLRP3 inhibitor Z48 obtained though docking-based virtual screening and structu…
View article: Associations between Life’s Essential 8 and abdominal aortic calcification among US Adults: a cross-sectional study
Associations between Life’s Essential 8 and abdominal aortic calcification among US Adults: a cross-sectional study Open
View article: Association of the triglyceride-glucose index with all-cause and cardiovascular mortality in patients with cardiometabolic syndrome: a national cohort study
Association of the triglyceride-glucose index with all-cause and cardiovascular mortality in patients with cardiometabolic syndrome: a national cohort study Open
Objective This study aimed to evaluate the association of triglyceride-glucose (TyG) index with all-cause and cardiovascular mortality risk among patients with cardiometabolic syndrome (CMS). Methods We performed a cohort study of 5754 ind…
View article: Supplemental Figure 2 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Supplemental Figure 2 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Supplemental Figure 2 shows the quantification of western blots shown in Figure 2A and 2B.
View article: Supplemental Figure 2 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Supplemental Figure 2 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Supplemental Figure 2 shows the quantification of western blots shown in Figure 2A and 2B.
View article: FIGURE 3 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
FIGURE 3 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Knockout of SIX4 reduces the efficacy of anti-PD-1 tumor suppression effect in vivo. A, Colony formation assays were performed in MC38 control and SIX4 knockout cells (gRNA2 and gRNA3) with representative images after MTT sta…
View article: Data from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Data from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
The cGAS/STING cytosolic DNA-sensing pathway plays a significant role in antitumor immunity. Expression of STING is tightly regulated and commonly reduced or defective in many types of cancer. We have identified SIX4 as a significant regul…
View article: Supplemental Figure 4 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Supplemental Figure 4 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Supplemental Figure 4 shows the quantification of western blots shown in Figure 2D.
View article: FIGURE 2 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
FIGURE 2 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
SIX4 modulates STING activation in colon cancer cells. A, MC38 SIX4 knockout cells and those with SIX4- or STING-reexpressing cells were treated with 10 µg/mL of DMXAA for 6 hours. Western blot analysis was performed to examine expr…
View article: Supplemental Figure 4 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Supplemental Figure 4 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Supplemental Figure 4 shows the quantification of western blots shown in Figure 2D.
View article: Supplemental Figure 1 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Supplemental Figure 1 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Supplemental Figure 1 shows the quantification of western blots shown in Figure 1A and 1B.
View article: FIGURE 3 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
FIGURE 3 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Knockout of SIX4 reduces the efficacy of anti-PD-1 tumor suppression effect in vivo. A, Colony formation assays were performed in MC38 control and SIX4 knockout cells (gRNA2 and gRNA3) with representative images after MTT sta…
View article: Supplemental Figure 1 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Supplemental Figure 1 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Supplemental Figure 1 shows the quantification of western blots shown in Figure 1A and 1B.
View article: Data from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Data from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
The cGAS/STING cytosolic DNA-sensing pathway plays a significant role in antitumor immunity. Expression of STING is tightly regulated and commonly reduced or defective in many types of cancer. We have identified SIX4 as a significant regul…
View article: FIGURE 1 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
FIGURE 1 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
SIX4 regulates expression of STING mRNA and protein. A, SIX4 expression was knocked out in MC38 cells by two gRNAs (gRNA2 and gRNA3). An empty vector (V) or SIX4-expressing vector (SIX4) was introduced into SIX4 knockout cells. Depl…
View article: Supplemental Figure 3 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Supplemental Figure 3 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Supplemental Figure 3 shows the quantification of western blots shown in Figure 2C.
View article: FIGURE 2 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
FIGURE 2 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
SIX4 modulates STING activation in colon cancer cells. A, MC38 SIX4 knockout cells and those with SIX4- or STING-reexpressing cells were treated with 10 µg/mL of DMXAA for 6 hours. Western blot analysis was performed to examine expr…